Meeting
2023 ASCO Annual Meeting
A phase II randomized clinical trial to assess toxicity and quality of life of patients with breast cancer with hypofractionated versus conventional fractionation radiotherapy with regional nodal irradiation.
Authors
Gabriel Oliveira Bernardes Gil
Rede Mater Dei, Nova Lima, Brazil
Gabriel Oliveira Bernardes Gil , Warne Pedro Andrade , Paulo Henrique Costa Diniz , Farley Soares Cantidio , Maria Luisa Vieira Gil , Izabella Nobre Queiroz , Conceição Aparecida Mediros Almeida , Paola Palmer Reis Caldeira , Marcos Regalin , Agnaldo Lopes Silva-Filho
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Local-Regional Therapy
Clinical Trial Registration Number
NCT04015531
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 588)
DOI
10.1200/JCO.2023.41.16_suppl.588
Abstract #
588
Poster Bd #
418
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295.
First Author: Jian Li Campian
Poster
2014 Breast Cancer Symposium
A phase II trial of once-weekly hypofractionated breast irradiation (WHBI): Interim analysis of cosmetic outcome and quality of life.
First Author: Anthony E. Dragun
Poster
2014 ASCO Annual Meeting
Randomized phase II trial comparing docetaxel with or without low-dose metronomic oral cyclophosphamide in first-line treatment of non-triple-negative advanced breast cancer.
First Author: Leiping Wang
Poster
2013 ASCO Annual Meeting
A phase II trial of an oral CDK 4/6 inhibitor, PD0332991, in advanced breast cancer.
First Author: Angela DeMichele